Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

14.5%

9 terminated out of 62 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

18%

11 trials in Phase 3/4

Results Transparency

23%

9 of 39 completed with results

Key Signals

9 with results81% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (12)
Early P 1 (1)
P 1 (8)
P 2 (11)
P 3 (7)
P 4 (4)

Trial Status

Completed39
Terminated9
Unknown7
Recruiting4
Active Not Recruiting2
Withdrawn1

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 39 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT04604522RecruitingPrimary

Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome

NCT05922761Phase 2Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT03656926Phase 3CompletedPrimary

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT00177918Completed

Prospective Evaluations of Infectious Complication in Lung Transplant Recipients

NCT07316829Active Not Recruiting

TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS

NCT04239989Phase 1TerminatedPrimary

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

NCT03657342Phase 3CompletedPrimary

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

NCT03603899Phase 1CompletedPrimary

Hp129 Xenon Imaging and BOS in Lung Transplantation

NCT04655508Phase 3Terminated

Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation

NCT04098445Recruiting

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

NCT06140901Not ApplicableRecruitingPrimary

Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans

NCT04039347Phase 3Active Not RecruitingPrimary

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

NCT05881538Not ApplicableCompletedPrimary

High Intensity Intervallic Training in Children With Bronchiolitis Obliterans

NCT04080232Not ApplicableCompletedPrimary

Study of Pulmonary MRI for the Diagnosis of Bronchiolitis Obliterans Syndrome After Allogeneic Stem Cell Transplantation

NCT02657837Unknown

Measures of Respiratory Health (MRH)

NCT02458274CompletedPrimary

Microparticles and Bronchiolitis Obliterans Syndrome

NCT05932316Not ApplicableUnknown

Evaluating Bronchodilator Response in Patients With Bronchiectasis

NCT01650545Phase 1Completed

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT03315741Phase 1CompletedPrimary

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT01175655Phase 1CompletedPrimary

A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation

Scroll to load more

Research Network

Activity Timeline